Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RC148 + ABBV-706
- Development stage
- Preclinical
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RC148 + ABBV-706 is an investigational combination therapy being developed by AbbVie for the treatment of solid tumors, particularly lung cancers. RC148 (also known as ABBV-1480) is a bispecific monoclonal antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), originally developed by RemeGen and licensed to AbbVie. ABBV-706 is a first-in-class antibody-drug conjugate (ADC) targeting seizure-related homolog protein 6 (SEZ6) conjugated to a topoisomerase 1 inhibitor (Top1i) payload. This combination leverages the dual immune checkpoint and angiogenic blockade of RC148 alongside the targeted cytotoxic activity of ABBV-706 to enhance antitumor efficacy and overcome resistance in advanced malignancies such as small cell lung cancer (SCLC).
- Other names
- ABBV-1480 + ABBV-706ABBV-706 + ABBV-1480ABBV-706 + RC148
02
Targets
Beyond the preview
Go deeper on RC148 + ABBV-706.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RC148 + ABBV-706.